Skip to main content

Table 3 Before and after values of 25-OHD and physical tests at baseline and 10 months (Time II) by target and reference groups (participants) and categories of 25-OHD concentrations (nmol/L) groups based on 25-OHD levels at baseline and compliers or non-compliers of supplement intake. Statistical significans with Wilcoxon

From: Long-term adherence and effects on grip strength and upper leg performance of prescribed supplemental vitamin D in pregnant and recently pregnant women of Somali and Swedish birth with 25-hydroxyvitamin D deficiency: a before-and-after treatment study

 

Target group

Reference group

N

46

25

 

Compliers

Non-compliers

Compliers

n (%)

38 (82.6%)

8 (17.4%)

23 (92%)

25(OH)D categorya

<10

10–24

25–50

<10

10–24

10–24

25–50

n

13

21

4

4

4

5

18

25(OH)D, mean (Std)

 Baseline

9.0 (0.0)

16.1 (5.0)

39.0 (15.1)

9.0 (0.0)

19.8 (3.1)

22.5 (1.6)

42.0 (6.7)

 10 m

50.5 (36.1)

57.9 (39.0)

60.3 (8.0)

15.0 (4.1)

22.6 (10.9)

66.3 (29.0)

66.6 (28.2)

 p

0.001

<0.001

0.068

0.102

0.715

0.043

0.001

Physical performance

 Grip (N), mean (Std)

       

 Baseline

118 (64)

162 (36)

193 (103)

166 (37)

171 (23)

242 (51)

262 (76)

 10 m

148 (65)

208 (46)

219 (54)

168 (37)

201 (43)

267 (34)

310 (59)

 p

0.039

<0.001

0.465

0.593

0.144

0.080

0.010

Inability to: Squat, n(%)

 Baseline

11 (84.6)

13 (61.9)

3 (75.0)

4 (100)

4 (100)

0 (0.0)

0 (0.0)

 10 m

0 (0.0)

4 (19.0)

1 (25.0)

2 (50.0)

2 (50.0)

1 (20.0)

0 (0.0)

 p

0.001

0.012

0.500

0.500

0.500

1.000

 

Stand on one leg, n (%)

       

 Baseline

3 (23.1)

5 (23.8)

0 (0.0)

2 (66.7)

1 (25.0)

0 (0.0)

1 (5.6)

 10 m

3 (23.1)

3 (14.3)

2 (50.0)

2 (66.7)

0 (0.0)

0 (0.0)

0 (0.0)

 p

1.000

0.688

0.500

1.000

1.000

 

1.000

Keep hip up, n (%)

      

 Base line

4 (30.8)

4 (19.0)

0 (0.0)

1 (25.0)

1 (25.0)

0 (0.0)

1 (5.6)

 10 m

0 (0.0)

0 (0.0)

0 (0.0)

1 (25.0)

0 (0.0)

0 (0.0)

0 (0.0)

 p

0.125

0.125

 

1.000

1.000

 

1.000

  1. Note: aCategorized 25-OHD values due to unmeasurable values and treatment strategies at baseline
  2. Bold data are significant